Please enable JavaScript to continue using this application.

Compare $ACAD vs $VCYT | Chartloom

Compare

$ACAD vs $VCYT

ACADIA Pharmaceuticals Inc · Veracyte Inc

ACAD

ACADIA Pharmaceuticals Inc

VCYT

Veracyte Inc

Compare $ACAD vs $VCYT

Comparing ACADIA Pharmaceuticals Inc and Veracyte Inc

ACADACADIA Pharmaceuticals Inc

VCYTVeracyte Inc

ACADACADIA Pharmaceuticals Inc

Market cap

$3.39B

P/E (TTM)

8.99x

Forward P/E (NTM)

23.42x

Forward P/S (NTM)

2.37x

Rev growth (TTM)

48.3%

YTD performance

-24.8%

52W performance

-7.2%

FCF yield

4.3%

VCYTVeracyte Inc

Market cap

$3.61B

P/E (TTM)

32.42x

Forward P/E (NTM)

24.66x

Forward P/S (NTM)

5.69x

Rev growth (TTM)

17.3%

YTD performance

6.7%

52W performance

28.9%

FCF yield

4.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ACAD

VCYT

Detailed metrics comparison

ACAD

ACADIA Pharmaceuticals Inc

VCYT

Veracyte Inc

Market Cap

ACAD$3.39B

VCYT$3.61B

Enterprise Value

ACAD$3.00B

VCYT$3.31B

Price

ACAD$19.78

VCYT$45.23

P/E Ratio

ACAD8.99x

VCYT32.42x

P/S Ratio

ACAD2.97x

VCYT6.42x

EV/Sales

ACAD2.64x

VCYT5.89x

EV/EBITDA

ACAD24.70x

VCYT24.67x

P/B Ratio

ACAD2.63x

VCYT2.65x

P/FCF Ratio

ACAD23.26x

VCYT21.74x

EV/FCF

ACAD20.62x

VCYT19.94x

PEG Ratio

ACAD0.13x

VCYT0.10x

Forward P/E (NTM)

ACAD23.42x

VCYT24.66x

Forward P/S (NTM)

ACAD2.37x

VCYT5.69x

Revenue (TTM)

ACAD$1.14B

VCYT$562M

Revenue Growth (YoY)

ACAD48.3%

VCYT17.3%

Forward Rev Growth

ACAD12.6%

VCYT11.4%

Gross Margin (TTM)

ACAD91.1%

VCYT71.7%

Operating Margin (TTM)

ACAD7.6%

VCYT19.6%

EBITDA Margin (TTM)

ACAD8.6%

VCYT22.5%

Net Margin (TTM)

ACAD33.4%

VCYT20.4%

FCF Margin (TTM)

ACAD12.8%

VCYT29.5%

Net Income (TTM)

ACAD$380M

VCYT$114M

FCF (TTM)

ACAD$146M

VCYT$166M

EPS (TTM)

ACAD$2.20

VCYT$1.40

ROE (TTM)

ACAD32.4%

VCYT8.6%

ROA (TTM)

ACAD24.4%

VCYT8.0%

ROIC (TTM)

ACAD32.4%

VCYT8.6%

Cash

ACAD$385M

VCYT$300M

Debt

ACAD$0

VCYT$0

Net Cash/Debt

ACAD$385M

VCYT$300M

Current Ratio (TTM)

ACAD3.39x

VCYT9.16x

Quick Ratio (TTM)

ACAD3.11x

VCYT8.60x

Debt/Equity (TTM)

ACAD0.00x

VCYT0.00x

Debt/Assets (TTM)

ACAD0.0%

VCYT0.0%

Interest Coverage (TTM)

ACADN/A

VCYTN/A

Net Debt/EBITDA (TTM)

ACAD0.00x

VCYT0.00x

Beta

ACAD0.91

VCYT2.00

52W Performance

ACAD-7.2%

VCYT28.9%

YTD Performance

ACAD-24.8%

VCYT6.7%

% from 52W High

ACAD-36.1%

VCYT-25.7%

% from 52W Low

ACAD2.4%

VCYT53.6%

Asset Turnover (TTM)

ACAD0.73x

VCYT0.39x

FCF Yield (TTM)

ACAD4.3%

VCYT4.6%

Earnings Yield (TTM)

ACAD11.2%

VCYT3.2%

Dividend Yield (TTM)

ACADN/A

VCYTN/A

Rule of 40

ACAD61.1

VCYT46.8

EV/GP/RG

ACAD0.09

VCYT0.60

Ticker research

View ACAD research View VCYT research

Metric	ACAD ACADIA Pharmaceuticals Inc	VCYT Veracyte Inc
Market & Valuation
Market Cap	$3.39B	$3.61B
Enterprise Value	$3.00B	$3.31B
Price	$19.78	$45.23
P/E Ratio	8.99x	32.42x
P/S Ratio	2.97x	6.42x
EV/Sales	2.64x	5.89x
EV/EBITDA	24.70x	24.67x
P/B Ratio	2.63x	2.65x
P/FCF Ratio	23.26x	21.74x
EV/FCF	20.62x	19.94x
PEG Ratio	0.13x	0.10x
Forward P/E (NTM)	23.42x	24.66x
Forward P/S (NTM)	2.37x	5.69x
Revenue & Growth
Revenue (TTM)	$1.14B	$562M
Revenue Growth (YoY)	48.3%	17.3%
Forward Rev Growth	12.6%	11.4%
Profitability
Gross Margin (TTM)	91.1%	71.7%
Operating Margin (TTM)	7.6%	19.6%
EBITDA Margin (TTM)	8.6%	22.5%
Net Margin (TTM)	33.4%	20.4%
FCF Margin (TTM)	12.8%	29.5%
Net Income (TTM)	$380M	$114M
FCF (TTM)	$146M	$166M
EPS (TTM)	$2.20	$1.40
ROE (TTM)	32.4%	8.6%
ROA (TTM)	24.4%	8.0%
ROIC (TTM)	32.4%	8.6%
Financial Health
Cash	$385M	$300M
Debt	$0	$0
Net Cash/Debt	$385M	$300M
Current Ratio (TTM)	3.39x	9.16x
Quick Ratio (TTM)	3.11x	8.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.91	2.00
52W Performance	-7.2%	28.9%
YTD Performance	-24.8%	6.7%
% from 52W High	-36.1%	-25.7%
% from 52W Low	2.4%	53.6%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.39x
FCF Yield (TTM)	4.3%	4.6%
Earnings Yield (TTM)	11.2%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	61.1	46.8
EV/GP/RG	0.09	0.60
Ticker research	View ACAD research	View VCYT research

Valuation

P/E Ratio

ACAD

8.99x

VCYT

32.42x

P/S Ratio

ACAD

2.97x

VCYT

6.42x

EV/FCF

VCYT

19.94x

ACAD

20.62x

Growth & revenue

Revenue Growth TTM

ACAD

48.3%

VCYT

17.3%

Forward Revenue Growth

ACAD

12.6%

VCYT

11.4%

Profitability & performance

Gross Margin

ACAD

91.1%

VCYT

71.7%

ROE

ACAD

32.4%

VCYT

8.6%

FCF Yield %

VCYT

4.6%

ACAD

4.3%

52-Week Performance

VCYT

28.9%

ACAD

-7.2%

Detailed metrics comparison

ACAD

ACADIA Pharmaceuticals Inc

VCYT

Veracyte Inc

Market Cap

ACAD$3.39B

VCYT$3.61B

Enterprise Value

ACAD$3.00B

VCYT$3.31B

Price

ACAD$19.78

VCYT$45.23

P/E Ratio

ACAD8.99x

VCYT32.42x

P/S Ratio

ACAD2.97x

VCYT6.42x

EV/Sales

ACAD2.64x

VCYT5.89x

EV/EBITDA

ACAD24.70x

VCYT24.67x

P/B Ratio

ACAD2.63x

VCYT2.65x

P/FCF Ratio

ACAD23.26x

VCYT21.74x

EV/FCF

ACAD20.62x

VCYT19.94x

PEG Ratio

ACAD0.13x

VCYT0.10x

Forward P/E (NTM)

ACAD23.42x

VCYT24.66x

Forward P/S (NTM)

ACAD2.37x

VCYT5.69x

Revenue (TTM)

ACAD$1.14B

VCYT$562M

Revenue Growth (YoY)

ACAD48.3%

VCYT17.3%

Forward Rev Growth

ACAD12.6%

VCYT11.4%

Gross Margin (TTM)

ACAD91.1%

VCYT71.7%

Operating Margin (TTM)

ACAD7.6%

VCYT19.6%

EBITDA Margin (TTM)

ACAD8.6%

VCYT22.5%

Net Margin (TTM)

ACAD33.4%

VCYT20.4%

FCF Margin (TTM)

ACAD12.8%

VCYT29.5%

Net Income (TTM)

ACAD$380M

VCYT$114M

FCF (TTM)

ACAD$146M

VCYT$166M

EPS (TTM)

ACAD$2.20

VCYT$1.40

ROE (TTM)

ACAD32.4%

VCYT8.6%

ROA (TTM)

ACAD24.4%

VCYT8.0%

ROIC (TTM)

ACAD32.4%

VCYT8.6%

Cash

ACAD$385M

VCYT$300M

Debt

ACAD$0

VCYT$0

Net Cash/Debt

ACAD$385M

VCYT$300M

Current Ratio (TTM)

ACAD3.39x

VCYT9.16x

Quick Ratio (TTM)

ACAD3.11x

VCYT8.60x

Debt/Equity (TTM)

ACAD0.00x

VCYT0.00x

Debt/Assets (TTM)

ACAD0.0%

VCYT0.0%

Interest Coverage (TTM)

ACADN/A

VCYTN/A

Net Debt/EBITDA (TTM)

ACAD0.00x

VCYT0.00x

Beta

ACAD0.91

VCYT2.00

52W Performance

ACAD-7.2%

VCYT28.9%

YTD Performance

ACAD-24.8%

VCYT6.7%

% from 52W High

ACAD-36.1%

VCYT-25.7%

% from 52W Low

ACAD2.4%

VCYT53.6%

Asset Turnover (TTM)

ACAD0.73x

VCYT0.39x

FCF Yield (TTM)

ACAD4.3%

VCYT4.6%

Earnings Yield (TTM)

ACAD11.2%

VCYT3.2%

Dividend Yield (TTM)

ACADN/A

VCYTN/A

Rule of 40

ACAD61.1

VCYT46.8

EV/GP/RG

ACAD0.09

VCYT0.60

Ticker research

View ACAD research View VCYT research

Metric	ACAD ACADIA Pharmaceuticals Inc	VCYT Veracyte Inc
Market & Valuation
Market Cap	$3.39B	$3.61B
Enterprise Value	$3.00B	$3.31B
Price	$19.78	$45.23
P/E Ratio	8.99x	32.42x
P/S Ratio	2.97x	6.42x
EV/Sales	2.64x	5.89x
EV/EBITDA	24.70x	24.67x
P/B Ratio	2.63x	2.65x
P/FCF Ratio	23.26x	21.74x
EV/FCF	20.62x	19.94x
PEG Ratio	0.13x	0.10x
Forward P/E (NTM)	23.42x	24.66x
Forward P/S (NTM)	2.37x	5.69x
Revenue & Growth
Revenue (TTM)	$1.14B	$562M
Revenue Growth (YoY)	48.3%	17.3%
Forward Rev Growth	12.6%	11.4%
Profitability
Gross Margin (TTM)	91.1%	71.7%
Operating Margin (TTM)	7.6%	19.6%
EBITDA Margin (TTM)	8.6%	22.5%
Net Margin (TTM)	33.4%	20.4%
FCF Margin (TTM)	12.8%	29.5%
Net Income (TTM)	$380M	$114M
FCF (TTM)	$146M	$166M
EPS (TTM)	$2.20	$1.40
ROE (TTM)	32.4%	8.6%
ROA (TTM)	24.4%	8.0%
ROIC (TTM)	32.4%	8.6%
Financial Health
Cash	$385M	$300M
Debt	$0	$0
Net Cash/Debt	$385M	$300M
Current Ratio (TTM)	3.39x	9.16x
Quick Ratio (TTM)	3.11x	8.60x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.91	2.00
52W Performance	-7.2%	28.9%
YTD Performance	-24.8%	6.7%
% from 52W High	-36.1%	-25.7%
% from 52W Low	2.4%	53.6%
Efficiency & Yields
Asset Turnover (TTM)	0.73x	0.39x
FCF Yield (TTM)	4.3%	4.6%
Earnings Yield (TTM)	11.2%	3.2%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	61.1	46.8
EV/GP/RG	0.09	0.60
Ticker research	View ACAD research	View VCYT research